Scott Kopetz

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Src continues aging: current and future clinical directions
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Cancer Res 13:7232-6. 2007
  2. pmc BRAF inhibitors in clinical oncology
    Van Morris
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center Houston, TX
    F1000Prime Rep 5:11. 2013
  3. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
  4. ncbi request reprint The promise of patient-derived xenografts: the best laid plans of mice and men
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 18:5160-2. 2012
  5. pmc Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:3677-83. 2009
  6. ncbi request reprint Adjuvant chemotherapy for stage II colon cancer
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 22:260-70; discussion 270, 273, 275. 2008
  7. doi request reprint Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:2000-5. 2008
  8. pmc Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    Scott Kopetz
    University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
    J Clin Oncol 28:453-9. 2010
  9. doi request reprint Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases
    Dipen M Maru
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 34:1287-94. 2010
  10. pmc Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases
    Junichi Shindoh
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:4566-72. 2012

Detail Information

Publications58

  1. ncbi request reprint Src continues aging: current and future clinical directions
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Cancer Res 13:7232-6. 2007
    ....
  2. pmc BRAF inhibitors in clinical oncology
    Van Morris
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center Houston, TX
    F1000Prime Rep 5:11. 2013
    ....
  3. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
    ..The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)...
  4. ncbi request reprint The promise of patient-derived xenografts: the best laid plans of mice and men
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 18:5160-2. 2012
    ..The ability of these models to inform clinical development and answer mechanistic questions will determine their ultimate use...
  5. pmc Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:3677-83. 2009
    ....
  6. ncbi request reprint Adjuvant chemotherapy for stage II colon cancer
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 22:260-70; discussion 270, 273, 275. 2008
    ..The only phase III clinical trial for stage II patients currently ongoing in the United States uses molecular classification as the basis for patient randomization...
  7. doi request reprint Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:2000-5. 2008
    ..It is unclear to what extent aspects of this "Critical Path Initiative" have been adopted in trial designs in metastatic colorectal cancer...
  8. pmc Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    Scott Kopetz
    University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
    J Clin Oncol 28:453-9. 2010
    ....
  9. doi request reprint Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases
    Dipen M Maru
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 34:1287-94. 2010
    ....
  10. pmc Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases
    Junichi Shindoh
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:4566-72. 2012
    ....
  11. pmc Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases
    Andreas Andreou
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 256:642-50. 2012
    ..We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)...
  12. ncbi request reprint Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Invest New Drugs 26:445-54. 2008
    ..0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules...
  13. pmc Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4484-92. 2011
    ..Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown...
  14. ncbi request reprint Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases
    Yun Shin Chun
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    JAMA 302:2338-44. 2009
    ....
  15. ncbi request reprint Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Am Coll Surg 210:934-41. 2010
    ..An increasing number of patients with synchronous colorectal liver metastases (CLM) are candidates for resection. The optimal treatment sequence in these patients has not been defined...
  16. doi request reprint Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  17. pmc Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy
    Andreas Andreou
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 257:1079-88. 2013
    ..To determine the impact of surgical margin status on overall survival (OS) of patients undergoing hepatectomy for colorectal liver metastases after modern preoperative chemotherapy...
  18. pmc A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:1439-45. 2012
    ..Because of its rarity, adenocarcinoma of the small intestine is frequently compared to adenocarcinoma of the colon, although the validity of this comparison is not known...
  19. doi request reprint Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases
    Yoji Kishi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:2870-6. 2010
    ..We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab, pathologic response, and hepatotoxicity after hepatic resection for CLM...
  20. doi request reprint Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Acta Oncol 49:474-9. 2010
    ..We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma...
  21. doi request reprint Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases
    Susan B Kesmodel
    Department of Surgical Oncology, Cancer Biology, Biostatistics, and Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:5254-60. 2008
    ..We therefore evaluated whether neoadjuvant BV is associated with an increase in postoperative complications in patients undergoing surgery for CRC liver metastases...
  22. pmc High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 29:1083-90. 2011
    ..The impact of complete resection in this well-selected group is controversial...
  23. ncbi request reprint Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2549-55. 2010
    ..We sought to explore the relationship between oxaliplatin induced hepatic sinusoidal injury, increases in spleen size, and the subsequent development of thrombocytopenia...
  24. doi request reprint Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 426, Houston, TX 77030, USA
    J Clin Oncol 27:2598-603. 2009
    ..We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in patients with advanced adenocarcinoma of small bowel or ampullary origin...
  25. pmc Comparison of prognostic genomic predictors in colorectal cancer
    Yun Yong Park
    Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e60778. 2013
    ..We compared five prognostic genomic predictors, the V7RHS, the ColoGuideEx, the Meta163, the OncoDX, and the MDA114, in terms of predicting disease-free survival in two independent cohorts of patients with colorectal cancer...
  26. doi request reprint Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
    Clin Colorectal Cancer 7:338-42. 2008
    ..Such trimodality therapy can result in durable palliation of symptoms and long-term survival for patients with recurrent CRC involving the duodenum and pancreas, even when other metastases are present...
  27. ncbi request reprint Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy
    Yoji Kishi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Ann Surg Oncol 16:614-22. 2009
    ..Whether neutrophil-to-lymphocyte ratio (NLR) predicts survival of patients with colorectal liver metastases (CLM) treated with systemic chemotherapy remains unclear...
  28. doi request reprint Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2038-45. 2008
    ..The objective of this retrospective study was to determine whether the addition of a platinum compound to 5-FU provided any benefit in the treatment of patients with metastatic SBA...
  29. ncbi request reprint Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival
    Yun Shin Chun
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 11:1498-504; discussion 1504-5. 2007
    ..The aim of this study was to compare the outcome of patients with CLM treated with preoperative chemotherapy followed by one- or two-stage hepatectomy...
  30. doi request reprint Perioperative chemotherapy for resectable hepatic metastases
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 371:963-5. 2008
  31. doi request reprint Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness
    Seth Politano
    University of Texas Health Science Center, Houston, TX, USA
    Clin Colorectal Cancer 7:55-9. 2008
    ..However, it is unclear which patient, disease, and treatment characteristics are associated with the utilization of a second-line regimen...
  32. ncbi request reprint Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury
    Julian H Slade
    Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Colorectal Cancer 8:225-30. 2009
    ..The literature on hepatic sinusoidal injury after oxaliplatin is reviewed and the proposed pathophysiology is discussed...
  33. doi request reprint Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors
    Michael J Overman
    University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Invest 26:794-9. 2008
    ..No responses were noted, but nine patients demonstrated prolonged stable disease in this heavily pretreated 5-FU refractory population...
  34. pmc ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma
    Michael P Kim
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e20636. 2011
    ..Understanding which pancreatic cancer cell populations possess tumor-initiating capabilities is critical to characterizing and understanding the biology of pancreatic CSCs towards therapeutic ends...
  35. doi request reprint CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab
    Piyaporn Boonsirikamchai
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    AJR Am J Roentgenol 197:W1060-6. 2011
    ..We also discuss the respective value of these criteria and the Response Evaluation Criteria in Solid Tumors (RECIST)...
  36. pmc Long-term survival and recurrence outcomes following surgery for distal rectal cancer
    Eric J Silberfein
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:2863-9. 2010
    ..The purpose of this study is to evaluate operative and pathologic factors associated with long-term survival and local recurrence outcomes in patients treated for distal rectal cancer...
  37. pmc The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy
    Christopher Lieu
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Colorectal Cancer 9:89-94. 2010
    ..Further evaluation with biomarkers will continue to define the molecular phenotype of patients with CRC who will benefit the most from Src-based therapy...
  38. pmc Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e65144. 2013
    ..We sought to molecularly classify ampullary adenocarcinomas in comparison to known adenocarcinomas of the pancreas, bile duct, and duodenum by gene expression analysis...
  39. pmc Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer
    Sang Cheul Oh
    Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gut 61:1291-8. 2012
    ....
  40. pmc Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy
    David Z Chang
    Departments of Gastrointestinal Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    J Hematol Oncol 2:18. 2009
    ..It should now become a standard practice that any patients being considered for EGFR targeted therapies have their tumors tested for KRAS status and only those with wild-type KRAS being offered such therapies...
  41. ncbi request reprint Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer
    David R Fogelman
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Anticancer Res 31:1417-20. 2011
    ..This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer...
  42. pmc Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course
    Michael P Herman
    Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 74:818-23. 2009
    ..Our goal was to determine the incidence, risk factors, and clinical course of SI fractures in patients treated with preoperative chemoradiation for rectal cancer...
  43. pmc Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress
    Scott Kopetz
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center and Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas 77030 4009, USA
    Cancer Res 69:3842-9. 2009
    ..These results suggest that Src inhibitors combined with oxaliplatin may have efficacy in metastatic colon cancer and may provide the first indication of a molecular phenotype that might be susceptible to such combinations...
  44. ncbi request reprint Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Colorectal Cancer 11:297-303. 2012
    ..Patients with advanced colorectal cancer have a poor prognosis once standard therapies fail. This retrospective study presents the characteristics and outcomes in 144 patients treated in phase I clinical trials...
  45. ncbi request reprint Use of research biopsies in clinical trials: are risks and benefits adequately discussed?
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 31:17-22. 2013
    ..Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed consents integrate and describe their use...
  46. doi request reprint Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis
    Christopher Lieu
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:6130-9. 2011
    ..Although agents targeting FGF signaling are early in development, the potential to target both the VEGF and FGF pathways may translate into improvements in the clinical care of cancer patients...
  47. ncbi request reprint Emerging drugs for colorectal cancer
    David R Fogelman
    MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 426, Houston, TX 77030, USA
    Expert Opin Emerg Drugs 13:629-42. 2008
    ..Our understanding of existing drugs, such as oxaliplatin and irinotecan, has become more refined. The incorporation of newer drugs such as bevacizumab and cetuximab has expanded treatment options as well...
  48. ncbi request reprint Return to intended oncologic treatment (RIOT): A novel metric for evaluating the quality of oncosurgical therapy for malignancy
    Thomas A Aloia
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Surg Oncol 110:107-14. 2014
    ....
  49. pmc CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
    Hui Ling
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Genome Res 23:1446-61. 2013
    ..Our results support a new mechanism of MYC and WNT regulation by the novel lncRNA CCAT2 in colorectal cancer pathogenesis, and provide an alternative explanation of the SNP-conferred cancer risk. ..
  50. pmc Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    Muling Mao
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, and Graduate School of Biomedical Sciences, University of Texas, Houston, TX 77030, USA
    Clin Cancer Res 19:657-67. 2013
    ....
  51. doi request reprint Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways
    Laura S Angelo
    Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 10:2094-103. 2011
    ..The combination of curcumin and an hsp inhibitor synergistically suppressed schwannoma cell growth. Our results provide a rationale for combining curcumin and KNK437 in the treatment of NF2...
  52. doi request reprint MicroRNAs, ultraconserved genes and colorectal cancers
    Simona Rossi
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Biochem Cell Biol 42:1291-7. 2010
    ....
  53. ncbi request reprint Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 19:11-7. 2005
    ..Combination regimens and second-line therapy should be offered to elderly patients who have adequate performance status and no contraindicated comorbid conditions, without regard for their chronological age...
  54. ncbi request reprint Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy
    Christopher R Kauffman
    Section of Interventional Radiology, Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 112:2283-8. 2008
    ..The purpose of this study was to review our institutional experience with PSE for cancer patients with thrombocytopenia because of splenic sequestration precluding the administration of systemic therapy (ST)...
  55. pmc Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer
    Jingjing Gong
    Authors Affiliations Department of Urology, Medical Oncology, Pathology, Cancer Therapy and Research Center, South Texas Veterans Health Care System, The University of Texas Health Science Center, San Antonio Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston and Department of carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, Texas
    Clin Cancer Res 20:1259-73. 2014
    ..The goal of this study is to determine whether targeting STAT3/NF-κB crosstalk with a natural product Nexrutine can inhibit inflammatory signaling in pancreatic cancer...
  56. doi request reprint Clinical findings of a palliative care consultation team at a comprehensive cancer center
    Navneet Dhillon
    Department of Palliative Care and Rehabilitation, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Palliat Med 11:191-7. 2008
    ..As clinical findings of these teams have been reported infrequently, we aim to describe the experience of our high-volume inpatient PCCT...
  57. ncbi request reprint Novel targets for systemic therapy of colorectal cancer
    Scott Kopetz
    GI Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 6:38-40. 2008
  58. ncbi request reprint PI-3-Kinase inhibitors in colorectal cancer
    N T Ihle
    University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Cancer Drug Targets 11:190-8. 2011
    ..How these goals may be achieved in the current oncology landscape is addressed in this review with an emphasis on how these agents fit the goal of achieving personalized medicine...